Skip to main content

Displaying 1241 - 1260 of 1511

Nov19

Workshop on Deception in Weight Loss Advertising

The FTC held a workshop to explore alternate approaches to reducing deceptive claims in advertising for weight-loss products. Following up on the issuance of the FTC staff report, Weight-Loss...

System Health Providers, Inc., and Genesis Physicians Group, Inc.

System Health Providers and its parent corporation, Genesis Physicians Group, Inc., settled charges that they collectively bargained with health insurance firms to accept proposed fee schedules; discouraged members from entering into contracts directly with payers; and refused to deal with health insurance firms and other third-party payers except on collectively agreed upon terms. The order prohibits the recurrence of the alleged practices and actions.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110196
Docket Number
C-4064

Announced Actions for October 11, 2002

Date
Following a public comment period, the Commission has approved the issuance of final consent orders and responses to the commenters of record in the matters concerning Philips Electronics and Okie...

R.T. Welter and Associates, Inc.

Eight Denver, Colorado physician groups specializing in obstetrics and gynecology and their non-physician agent settled allegations that the practice group and other physicians entered into collective contracts in an effort to increase prices and terms of services when dealing with health insurance firms and other third-party payers.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110175
Docket Number
C-4063

Announced Action for October 4, 2002

Date
Following a public comment period, the Commission has approved the issuance of a modified final consent order in the matter concerning Biovail Corporation (Biovail) and its branded drug Tiazac...
Sep09

Workshop on Health Care and Competition Law and Policy

-
The FTC held a public workshop on the implications of competition law and policy for health care financing and delivery. The workshop considered the impact of competition law and policy on the cost...

Announced Action for September 6, 2002

Date
Following a public comment period, the Commission has approved a final consent order, without modifications, and a letter to the commenter of record in the matter concerning Immunex Corporation and...

Amgen Inc. and Immunex Corporation

Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and interleukin-1 (IL-1) inhibitors. The consent order requires the firms to sell all of Immunex's assets related to Leukine -a neutrophil regeneration factor -to Schering AG; license certain intellectual property rights to TNF inhibitors to Serono S.A.; and license certain intellectual property rights related to IL-1 inhibitors to Regeneron Pharmaceuticals Inc.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0210059
Docket Number
C-4056

Announced Actions for August 20, 2002

Date
The Commission has approved the issuance of a final consent order in the matter concerning Biovail Corporation and Elan Corporation, plc, and authorized a response letter to be sent to the one...